Qva149 Significantly Lowers The Rate And Risk Of Moderate Or Severe COPD Exacerbation Versus Salmeterol/fluticasone In Patients With Moderate To Severe COPD: The Lantern Study

被引：0
|
作者：
Zhong, N. [1 ]
Wang, C. [2 ]
Zhou, X. [3 ]
Zhang, N. [1 ]
Patalano, F. [4 ]
Humphries, M. [5 ]
Wang, L. [5 ]
Banerji, D. [6 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China
[2] Third Mil Med Univ, Inst Resp Dis, Xin Qiao Hosp, Chongqing, Peoples R China
[3] Third Mil Med Univ, Southwest Hosp, Dept Resp Med, Chongqing, Peoples R China
[4] Novartis Pharma AG, Basel, Switzerland
[5] Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China
[6] Novartis Pharmaceut, E Hanover, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3978
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Qva149 Is Safe And Well Tolerated In Patients With Moderate-To-Severe COPD: Flight3, A 52week Safety Study
    Ferguson, G. T.
    FowlerTaylor, A.
    Thach, C.
    Wang, Q.
    Schubert-Tennigkeit, A. A.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [22] QVA149 IS MORE EFFICACIOUS THAN TIOTROPIUM AND SALMETEROL/FLUTICASONE COMBINATION (SFC) IN IMPROVING PATIENT-REPORTED OUTCOMES AND LUNG FUNCTION IN COPD PATIENTS WITH MODERATE TO SEVERE BASELINE DYSPNOEA: THE IGNITE TRIALS
    Wark, P.
    Mahler, D.
    Keininger, D.
    Fogel, R.
    Mezzi, K.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 25 - 25
  • [23] Effect of fluticasone propionate/salmeterol on exercise endurance in moderate-severe COPD
    Yang, Wenlan
    Liu, Jinming
    Gao, Beilan
    Cheng, Kebing
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [24] Efficacy and Safety of QVA149, a Fixed-Dose Combination of Indacaterol and Glycopyrrolate in Symptomatic Patients With Moderate to Severe COPD: Effect of Gender
    Yadao, Anthony
    Fucile, Sebastian
    Shen, Steven
    Ayers, Tim
    Banerji, Donald
    Fogel, Robert
    CHEST, 2016, 150 (04) : 822A - 822A
  • [25] Qva149 Improves Lung Function To A Greater Extent Than Monocomponents In Patients With Moderate-To-Severe COPD: The Flight1 Study
    Kerwin, E. M.
    FowlerTaylor, A.
    Ayers, T.
    Thach, C.
    Maitra, S.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [26] EFFECT OF FLUTICASONE PROPIONATE/SALMETEROL ON EXERCISE ENDURANCE IN MODERATE-SEVERE COPD
    Yang, W-L
    Liu, J-M
    Sun, X-G
    Gao, B-L
    Cheng, K-B
    RESPIROLOGY, 2011, 16 : 90 - 90
  • [27] QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
    Mahler, Donald
    Keininger, Dorothy
    Fogel, Robert
    Mezzi, Karen
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [28] Comparison of COPD Exacerbations With Once-Daily QVA149 Versus Twice-Daily Salmeterol/Fluticasone Combination: The ILLUMINATE Study
    Bateman, Eric
    Vogelmeier, Claus
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [29] Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study
    Vogelmeier, Claus
    Bateman, Eric
    Pallante, John
    Bryant, Hannah
    Alagappan, Vijay
    D'Andrea, Peter
    He, Ellie
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [30] COMPARISON OF COPD EXACERBATIONS WITH ONCE-DAILY QVA149 VERSUS TWICE-DAILY SALMETEROL/FLUTICASONE COMBINATION: THE ILLUMINATE STUDY
    Vogelmeier, C.
    Bateman, E. D.
    Chen, H.
    Banerji, D.
    THORAX, 2013, 68 : A184 - A185
12345